A cancer cell with mutated p53 still needs energy
Within the hostile ecosystem of a tumor, bacteria have long been overlooked as mere bystanders — but researchers at the University of Illinois Chicago are now asking what weapons these microbial residents might carry. By studying bacterial proteins that evolved to survive inside tumors, the team designed a synthetic peptide called aurB that cuts off cancer cells' energy supply at its source, the mitochondria, working independently of the genetic mutations that have long undermined other therapies. It is a reminder that nature's most useful tools are sometimes hidden in the places we least expect to look.
- Cancer cells depend on relentless energy production to grow and spread, and that dependency has now been turned against them by a peptide engineered from tumor-dwelling bacteria.
- Earlier bacterial-derived treatments stumbled because they required functional p53, a gene mutated in many cancers — leaving a wide swath of patients without options.
- aurB bypasses that flaw entirely, targeting ATP synthase in the mitochondria directly, a vulnerability shared by virtually all cancer cells regardless of their genetic profile.
- In mouse models of treatment-resistant prostate cancer, combining aurB with radiation dramatically slowed tumor growth and suppressed bone metastasis without significant toxicity.
- With a patent secured and human clinical trials on the horizon, the researchers believe the tumor microbiome may be a vast, largely untapped library of future cancer drugs.
Cancer cells are voracious consumers of energy, and researchers at the University of Illinois Chicago have found a way to exploit that dependency — by borrowing tools from bacteria already living inside tumors. For years, these microbial residents were dismissed as incidental. Tohru Yamada's team began asking instead whether they might carry proteins worth weaponizing.
Yamada's earlier work with bacterial cupredoxin proteins showed promise but carried a critical limitation: the treatment depended on p53, a tumor-suppressor gene that is frequently and variably mutated in cancer. A therapy tied to p53 function was inherently unreliable. The team needed something that worked regardless of a patient's genetic profile.
Returning to tumor samples from breast cancer patients, they sequenced the microbial DNA present and identified a cupredoxin protein called auracyanin. From it, they designed a synthetic peptide named aurB. In laboratory tests, aurB entered cancer cell mitochondria and bound directly to ATP synthase — the enzyme that produces ATP, the cell's fundamental energy currency. Without it, tumor cells cannot survive.
The results became especially striking when aurB was paired with radiation in mouse models of hormone-resistant prostate cancer. Tumor growth slowed dramatically, bone metastasis was substantially inhibited, and no significant toxicity appeared. Because aurB targets the mitochondria rather than the cell's internal suppression machinery, it sidesteps p53 entirely — a vulnerability that is universal across cancer types.
Yamada has patented aurB and is preparing for human clinical trials, but he frames this as an opening move rather than a conclusion. Tumors harbor many bacterial species, each potentially carrying proteins with therapeutic value. The cupredoxins are only the first family his team has explored, and he believes many others remain to be discovered — suggesting that one of medicine's most powerful future arsenals may already be living, quietly, inside the disease itself.
Cancer cells are hungry. They burn through energy at a rate that would exhaust a normal cell, demanding constant fuel to grow and divide. Researchers at the University of Illinois Chicago have found a way to exploit that hunger by cutting off the supply—and they borrowed the idea from an unlikely source: bacteria living inside tumors themselves.
Tumors are not sterile environments. They harbor microorganisms as part of their ecosystem, and for years scientists dismissed these bacteria as incidental passengers. More recently, that view has shifted. Tohru Yamada and his team at UIC began asking whether these microbial residents might actually contain useful compounds, proteins that had evolved to thrive in the hostile tumor landscape. If bacteria could survive there, perhaps they had weapons worth studying.
Yamada's earlier work identified a bacterial protein called a cupredoxin that could slow tumor growth, but it had a critical flaw. The treatment relied on a gene called p53, which acts as a tumor suppressor in healthy cells. The problem is that p53 is frequently mutated in cancer, and those mutations vary widely from patient to patient. A therapy dependent on p53 function worked in some cases but failed in others. Yamada wanted something better—a treatment that would work regardless of p53 status.
The team returned to the bacteria. They analyzed tumor samples from breast cancer patients, sequenced the DNA to identify which microbes were present, and found one species carrying a cupredoxin protein called auracyanin. Using this as a blueprint, they designed a synthetic peptide they named aurB. In laboratory tests, aurB proved to have a direct target: it entered the mitochondria of cancer cells and bound to ATP synthase, the enzyme responsible for manufacturing ATP, the cell's primary energy currency. Without ATP production, tumor cells cannot survive or multiply.
The real breakthrough came when they tested aurB in combination with radiation, the standard treatment for prostate cancer. In mouse models of prostate cancer that had stopped responding to hormone therapy, the combination was striking. Tumor growth slowed dramatically. The peptide showed no signs of significant toxicity. When the researchers used a bone metastasis model—a particularly aggressive form of the disease—they saw substantial inhibition of tumor spread.
What makes this approach elegant is its independence from p53. By targeting the mitochondria directly rather than relying on the cell's internal tumor-suppression machinery, aurB sidesteps the genetic variations that have made earlier treatments unreliable. A cancer cell with mutated p53 still needs energy. It still depends on ATP synthase. The vulnerability is universal.
Yamada has secured a patent for aurB and is now preparing to move the therapy into human clinical trials. But he sees this as just the beginning. Tumors contain many bacterial species, and each one may harbor proteins with therapeutic potential. The cupredoxins are only the first family of compounds his team has explored. "There are many other bacterial proteins that could be a source of cancer drugs," Yamada said. "We simply haven't tried them yet." The research suggests that the answer to cancer may not lie in attacking the disease head-on, but in learning to weaponize the microscopic world that already exists within it.
Citações Notáveis
The mitochondria are very important for a cell to survive; they are the energy factories. Many cancer cells exhibit altered mitochondrial number and activity because a cancer cell has to grow aggressively and rapidly. Therefore, the mitochondria would be an ideal target for cancer therapy.— Tohru Yamada, senior author, University of Illinois Chicago
There are many other bacterial proteins that could be a source of cancer drugs. We simply haven't tried them yet.— Tohru Yamada
A Conversa do Hearth Outra perspectiva sobre a história
Why does combining this peptide with radiation work so much better than either treatment alone?
Radiation damages cancer cells directly, but they're remarkably good at repairing themselves if they have energy. aurB starves them of that energy, so they can't mount an effective repair response. The two approaches work on different timescales—radiation is acute damage, aurB is metabolic collapse.
You mentioned p53 mutations are common in cancer. How common are we talking?
Very. P53 is mutated in roughly half of all human cancers. That's why the earlier bacterial peptide, the one that depended on p53 function, had such limited reach. aurB bypasses that problem entirely.
If cancer cells need energy to survive, why haven't we targeted ATP synthase before?
We have, in various ways. But most approaches have been toxic to normal cells too—they need ATP as much as cancer cells do. What's different here is that the peptide seems to accumulate in tumor cells preferentially. The bacteria that live in tumors may have evolved proteins that are particularly good at penetrating cancer cell membranes.
So the bacteria are essentially teaching us how to kill cancer?
Exactly. The bacteria survive in a hostile environment by developing proteins that work in that specific context. We're reverse-engineering their survival strategies and turning them into weapons against the tumor itself.
What happens next—how far away are human trials?
They have the patent. They're working on the regulatory pathway now. These things move slowly, but the preclinical data is strong enough that there's real momentum. The question isn't whether this will reach patients, but when.
And if aurB works in humans, what does that mean for cancer treatment broadly?
It opens an entirely new library of drug candidates. We've been looking at bacteria as contaminants or curiosities. If this works, it reframes them as a pharmaceutical resource. Yamada's team has barely scratched the surface of what's in those tumors.